Pfizer said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. The data offer early evidence that the injection can ...
An oral drug from Pfizer causes a similar amount of weight loss as the blockbuster Ozempic injection, made by rival Novo Nordisk, according to results from a phase two clinical trial. The results were ...
NVO and PFE clash as the obesity market heats up, with shifting strategies, pipeline bets and growth pressures reshaping their investment outlook.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results